This study focuses on presympathetic neurons of the rostral ventrolateral medulla (RVLM) that regulate sympathetic vasomotor tone. Many neurotransmitters are co-localized in RVLM neurons and are released under specific conditions to modulate efferent homeostatic responses. Of particular interest here, are two peptides co-localized in catecholaminergic RVLM neurons: catestatin, and pituitary adenylate cyclase-activating polypeptide (PACAP).
Introduction:
Hypertension is a major human health problem that is in large part due to increased sympathetic drive that emanates from the rostral ventrolateral medulla (RVLM) (42, 44, 45) .
Central neural mechanisms maintain arterial blood pressure by integrating information from reflexes, central behavioral and emotional states to alter efferent sympathetic and parasympathetic activity according to need (18, 44, 45) . The RVLM plays a critical role in this system as the final integrative pathway in the regulation of sympathetic tone and cardiovascular adaptive reflexes (e.g. the baroreceptor and chemoreceptor reflexes) (45) . The RVLM contains a functionally heterogeneous cell population that includes barosensitive, presympathetic (C1) neurons which project to sympathetic preganglionic neurons (SPN) in the intermediolateral cell column of the spinal cord. SPN regulate sympathetic outflow through innervation of the adrenal medulla and sympathetic post-ganglionic neurons that project to the heart, kidneys and blood vessels. Increased excitability of RVLM neurons, SPN and by extension sympathetic drive targeting organs and blood vessels in the periphery, is critically implicated in the pathophysiology of essential hypertension, a major underlying cause of morbidity and mortality.
Many neurotransmitters are co-localized within adrenergic (C1) and non-adrenergic RVLM bulbospinal neurons, suggesting that interactions occur if these neurotransmitters are released together, such interactions will affect the excitability of SPN and the sympathetic outflow reaching the target organs in the periphery. However, the nature and importance of such interactions remains unclear. Glutamate is the major excitatory transmitter released by these neurons, but many metabotropic transmitters are also present, and modulate SPN activity, including: enkephalin (51) , neuropeptide Y (38, 46) and Substance P (27) . We hypothesize that dysfunction of, or interaction between, co-localized or temporally co-released neurotransmitters arising from the RVLM, Raphé, hypothalamus or other sites, may contribute to the increased excitability of the region and SPN in essential hypertension. Two vesicular peptides of interest in the current study are catestatin (human chromogranin A 352-372 ), a vasoactive chromogranin A (CgA) cleavage product (32), and pituitary adenylate cyclase-activating polypeptide (PACAP) (39) . Catestatin is contained within 88% of C1 RVLM neurons, and PACAP-38 is expressed in 85% of bulbospinal C1 RVLM neurons, indicating extensive co-localization of these neurotransmitters in this nucleus (9, 13) . The separate effects of these peptides have been studied following injection into the intrathecal space and into the RVLM, (9, 12, 49, 50) but the physiological significance of this extensive co-localization is unclear.
Catestatin and PACAP are both vasodilator peptides in the periphery (11, 54) . Intrathecal PACAP increases splanchnic sympathetic nerve activity (sSNA) and heart rate (HR), but does not affect mean arterial blood pressure (MAP) (9) . Intrathecal catestatin on its own has no effect on MAP, sSNA, or HR, but is pressor and sympathoexcitatory in the RVLM and significantly enhances the sympathetic baroreflex; though it blunts the hypoxic chemoreflex and somatosympathetic reflexes (13) . Catestatin is cardioprotective, and blunts the sympathoexcitatory response to spinal stimulation in the pithed rat (23, 35, 43) . In spinal cord, catestatin stabilizes cardiovascular parameters by attenuating the responses to nicotine and isoproterenol (12) . Catestatin may attenuate the ability of adenylate cyclase and phospholipase C to act intracellularly. Since adenylate cyclase and phospholipase C are two systems engaged by PACAP through the PAC 1 receptor, we hypothesized that co-application 5 of catestatin prior to PACAP would alter the ability of PACAP to influence sympathetic nerve activity, blood pressure and heart rate.
Here, we investigate two different catestatin pre-treatment regimes to examine the temporal effects of catestatin on the response to PACAP. The principal objective of this study was to determine the role of catestatin in central cardiovascular modulation of the intrathecal PACAP-38 response, and to determine if co-release of PACAP and catestatin within the circuitry controlling sympathetic vasomotor tone may be critical in mediating essential hypertension. Secondly, we aimed to determine the separate effects of intrathecal catestatin and PACAP-38 on basal cardiovascular parameters and reflex control of the cardiovascular system.
Methods:
All procedures and protocols were approved by the Macquarie University Animal Ethics Committee in accordance with the guidelines set forth by the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Experiments were conducted on adult male Sprague-Dawley rats (400-550 g; Animal Resource Centre, Western Australia) in accordance with these guidelines.
Surgical Procedures
General surgical methods were carried out as previously described (12, 19) . Briefly, anesthesia was induced in male Sprague-Dawley rats (n = 22) with a bolus of urethane (ethyl carbamate, 10%, 1.3 g/kg in 0.9% saline w./v., i.p.; Sigma-Aldrich). Additional doses of urethane (30 -40 mg in 10% solution, i.v.) were given as needed to maintain a stable degree of anesthesia. Absence of the withdrawal reflex or lack of arterial pressure changes (>10 mmHg) in response to a hind paw pinch were used to assess the depth of anesthesia. The right jugular vein and common carotid artery were cannulated for administration of fluids and measurement of arterial blood pressure, respectively. The trachea was cannulated to allow for artificial ventilation (rodent ventilator; UGO Basile, Biological Research Apparatus, Italy).
Rats were bilaterally vagotomized, paralyzed (pancuronium bromide; 0.8 mg bolus, followed by an infusion of 10% pancuronium in 0.9% saline w/v -2 ml/h; Astra Pharmaceuticals), and ventilated with 100% oxygen supplemented room air. End-tidal CO 2 was maintained between 4.0% and 5.0% by altering the stroke volume and frequency of ventilation as needed (Capstar-100 CO 2 analyzer; CWE Inc. USA). Core temperature was maintained at 37±0.5°C.
The left splanchnic sympathetic nerve was isolated, dissected, and prepared for recording on a bipolar platinum electrode immersed in paraffin oil. Nerve activity was amplified (1 k-100 k X gain), filtered (30 -3,000 Hz), and sampled at 5,000 Hz using an ADC system (model 1401, CED, Cambridge, UK) and Spike 2 analysis software (version 7.07).
An intrathecal catheter (polyvinylchloride tubing: ID, 0.2 mm; OD, 0.5 mm, Critchley Electrical Products), with a dead space of approximately 6 µL was inserted through an incision in the dura mater at the atlanto-occipital junction and passed caudally in the subarachnoid space to the level of T5/6. Intrathecal injections (PACAP-38, 1mM, Auspep Pty.
Ltd., Australia; catestatin, 0.1 mM, Phoenix Pharmaceuticals) were given in volumes of 10 µL, followed by 6 µL of vehicle (10 mM phosphate buffered saline, PBS; pH 7.4) using a 25 µL Hamilton syringe.
Experimental protocol.
All intrathecal injections (10µl of drug washed in with 6µl of 10mM phosphate buffered 0.9% saline (PBS)) were made using a Hamilton syringe. All rats received control injections of the vehicle, PBS (10µl of PBS washed in with 6µl PBS), 30 minutes prior to treatment as described below. Cardiovascular reflexes, viz., the baroreflex and peripheral chemoreflex, were each evoked twice at specified times both post-vehicle control, and during each of the conditions described below. The sympathetic baroreflex was tested using intravenous injections of phenylephrine (PE; 10 µg/kg). Carotid chemoreceptors were activated by ventilating with N 2 for 12 seconds (isocapnic anoxia).
Catestatin pre-treatment (15 minutes) followed by PACAP. GraphPad Software La Jolla, CA). Statistical significance was determined using one-or twoway ANOVA with Bonferroni's correction. P < 0.05 was considered significant.
Results:
In the presence of catestatin, PACAP-38 is hypotensive, and increases HR and sSNA.
Catestatin(90)+PACAP-38 has a significant depressor effect on MAP compared to baseline (-30 ± 1 mmHg from a baseline of 115 ± 9 mmHg; P < 0.01; n = 4) and the untreated PACAP-38 response (P < 0.05). The depressor response reached a maximum approximately 10 minutes after the PACAP-38 injection, and remained below baseline for the duration of the experimental period (60 minutes; Figures 1B and 2A) . The decrease observed following the vehicle-treated PACAP-38 injection was amplified by pre-treatment with catestatin ( Figure   2A ).
Catestatin (15) The sSNA response to intrathecal PACAP-38 15 or 90 minutes after catestatin pre-treatment was not significantly altered when compared to the vehicle-treated intrathecal PACAP-38 response ( Figure 2C ).
Pre-treatment with catestatin increases barosensitivity and chemosensitivity after intrathecal injection of PACAP.
PACAP-38 administered after pre-treatment with catestatin significantly increases barosensitivity, and is more effective than either PACAP-38 or catestatin individually (P < 0.001; Figure 3 ). The slopes of the baroreflex curves generated after catestatin(90)+PACAP-38 were significantly increased at both 10-(P < 0.01; n = 5) and 60-minute (P < 0.01; n = 5) time points post-PACAP-38 injection (Figure 3 ).
The response to hypoxia following PACAP-38 administion, 90 minutes after pre-treatment with catestatin, is a significant increase in the range of the MAP response (P < 0. 01; Figure   4A ) and the slope of the sSNA response (P < 0. 01; Figure 4C) . Specifically, the range of the MAP response to hypoxia is increased after catestatin (90)+PACAP, at both 10-(P < 0.05; Figure 4A ) and 60-minute (P < 0.05; Figure 4A ) post-PACAP-38 time points, when compared with the responses to hypoxia after catestatin(15)+PACAP-38. The slope of the sSNA response to hypoxic stimuli after catestatin (90)+PACAP-38 was significantly augmented at 60 minutes post-PACAP-38 (P < 0.05). The slope of the sSNA response to hypoxia 60 minutes after catestatin (90)+PACAP-38 was significantly greater than the response observed after catestatin(15)+PACAP-38 (P < 0.05; Figure 4C ). The sSNA range was not effected following catestatin(90)+PACAP-38 ( Figure 4B) , however, the sSNA range was attenuated following catestatin(15)+PACAP-38 when compared to PACAP-38 alone (P < 0. 05; Figure 4B ).
Intrathecal catestatin does not significantly affect MAP, HR, and sSNA.
Intrathecal catestatin did not significantly affect MAP, HR, or sSNA (MAP = Δ5 ± 2 mmHg; HR = Δ12 ± 8 bpm; sSNA = Δ9 ± 6%; n = 8; Figures 1 and 2 ) for up to 90 minutes after administration when compared to the vehicle response (MAP = Δ12 ± 3 mmHg; HR = Δ5 ± 10 bpm; sSNA = Δ22 ± 12%; n = 4; Figures 1, and 2 ). There was no significant difference between the peak response to catestatin and the vehicle response at both time points for all measured parameters (Figures 1 and 2 ).
Intrathecal catestatin does not significantly affect baroreflex or chemoreflex sensitivity. 
Discussion:
The data demonstrate a potent synergistic effect of catestatin and PACAP-38 in the spinal cord. Both peptides are present in nerve terminals that surround SPN, and both peptides exert potent cardiovascular effects elsewhere in the brain, but have no effect on blood pressure or reflexes on their own in the spinal cord (9, 12, 13) . A key difference however, is that catestatin delivered intrathecally does not affect MAP, HR, sSNA or adaptive reflexes (12) .
PACAP on the other hand does not affect MAP, but does cause increases in HR and sSNA (9) .
The primary, novel findings of this study are first, that intrathecal catestatin, followed by intrathecal PACAP, significantly decreases MAP, but has no effect on the PACAP-38-induced sympathoexcitation. Secondly, pre-treatment with catestatin (90 minutes) before intrathecal administration of PACAP-38, enhances baroreflex and chemoreflex sensitivity. (24) . Therefore, the results observed here may be due to partial blockade of PAC 1 receptors by catestatin, with a change in the balance towards excitation of adrenaline-releasing pathways that cause and increase in heart rate, a large decrease in peripheral resistance, and a subsequent fall in blood pressure (14, 16) . However, further study, such as catecholamine measurement, is required to support this hypothesis.
Catestatin may increase the excitability of SPN or other spinal interneurons, resulting in augmented activation of adrenal chromaffin cells and other sympathetic targets. PACAP-38-induced activation of SPN projecting to the adrenal gland may increase the release of catestatin, catecholamines, PACAP-38 and other co-stored substances. In particular, the hypotensive response to catestatin(90)+PACAP-38 may be a result of increased epinephrine release that, in turn, enhances peripheral vasodilation (3, 23, 40) .
Intravenous catestatin (to reach an extracellular concentration of 6mmol/L; 0.3µmol/L/rat) caused histamine release-mediated hypotension following sympathoexcitation by electrical stimulation. Catestatin significantly increased plasma epinephrine by 11-fold, while having no effect on plasma norepinephrine (23); this contradicts in vitro studies that demonstrate the ability of catestatin to inhibit catecholamine release. Therefore, the endocrine effect of intravenous catestatin in the rat appears to be that of indirect vasodilation. In general, catestatin acts to stabilize baseline conditions in several in vivo and in vitro models (2, 5, 15, 30, 34, 48) . As such, the role of catestatin may not be apparent until an appropriate stimulus is applied. Here catestatin appears to prime the system so that PACAP-38 may induce hypotension and increase barosensitivity and chemosensitivity. As noted above, we speculate that this occurs as a result of activation of SPN that project to epinephrine secreting chromaffin cells.
Baroreceptor-induced sympathoinhibition is mediated by inhibition of tonically active RVLM neurons (17, 44, 45) . The present study demonstrates that pre-treatment with catestatin primes this pathway so that PACAP-38 significantly increases sympathetic baroreflex sensitivity. Catestatin(90)+PACAP-38 may result in either disfacilitation or direct inhibition at the spinal level to augment baroreflex sensitivity.
Hypoxia causes a rapid and reversible excitation of bulbospinal sympathoexcitatory RVLM neurons that monosynaptically project to SPN. Sympathetic excitation elicited by hypoxia requires glutamatergic transmission (52) . Intrathecal pre-treatment of catestatin before administration of PACAP-38 increases the range of the pressor response and markedly augments the slope and range of the sSNA response to the chemoreflex.
Catestatin alone does not alter the tonic or reflex control of the cardiovascular system: Intrathecal injection of catestatin did not affect basal MAP, sSNA, and HR (12) (Figures 1   and 2 ), or the sympathetic baroreflex, or the hypoxic chemoreflex (Figures 3 and 4) .
The mechanism by which catestatin acts in the spinal cord is unknown. Catestatin exerts divergent actions depending on the tissue being investigated (23, 30, 34 ). In the periphery, catestatin causes vasodilation (11) , and has antimicrobial actions in the human epidermis, suggesting a role for catestatin in the cutaneous defense system (47) . In the brainstem, it is sympathoexcitatory and enhances sympathetic barosensitivity (13) .
The first characterized reported action of catestatin was as a nAChR antagonist that blocks nicotine-induced catecholamine secretion from PC12 cells (31), bovine adrenal chromaffin cells (32), and rat hippocampal neurons (4) . Recent studies reported that catestatin affects many intracellular signaling pathways (7, 34, 55) . For example, catestatin inhibits the actions of nicotine and isoproterenol in the intrathecal space, most likely through interactions with nAChR and β-adrenoceptors (12) . The finding that intrathecal catestatin does not exert any effects on its own may be because constitutively active nAChR are not present on SPN, the effects of catestatin are not visible under basal conditions, or that catestatin causes many opposing effects that are balanced under normotensive conditions, resulting in no net change.
Intrathecal administration of catestatin does not affect the baroreflex or the cardiovascular responses to hypoxic chemoreflex stimulation at any time point. This indicates that intrathecal catestatin on its own is not involved in the reflex control of the cardiovascular system. Previously, we reported that microinjection of catestatin into the RVLM increased barosensitivity and attenuated chemosensitivity (13) . Differences in injection method, site, and dose, may explain this discrepancy. slices from juvenile rats (25) , and is localized in at least 82% of C1 presympathetic bulbospinal RVLM neurons (9) . Functional evidence supports these findings; intrathecal PACAP-38 causes a prolonged tachycardia and sympathoexcitation in multiple sympathetic beds through activation of SPN, but no change in MAP (9, 19) . Previous studies report conflicting findings regarding the MAP response to PACAP-38; Lai et al. found a significant increase in MAP (25) , while others saw no change in MAP (9) . This study supports the earlier findings that PACAP-38 does not affect MAP in vivo (9, 19) . Despite the welldescribed effects of intrathecal PACAP-38 on the cardiovascular system, the role of PACAP-38 in the reflex control of the cardiovascular system is relatively unstudied.
Intrathecal PACAP-38 does not affect the slope of the baroreflex or the hypoxic chemoreflex.
The results demonstrate that while spinal PACAP-38 appears to have little effect on adaptive reflexes under basal conditions. However, following pre-treatment with catestatin effects are apparent. To date, this is the only study to examine the role that PACAP-38 plays in the chemoreflex. The finding that the sympathetic baroreflex is unaffected is in contrast to previous study examining HR barosensitivity in the anesthetized rainbow trout (26) . Apart from the obvious differences in dose, species, and injection site, the baroreflex sensitivity was calculated using HR rather than sSNA. PACAP-38 did not change HR in the study by Lancien et al., likely explaining the observed depression in barosensitivity (26) . Here we used direct recordings from barosensitive, pulse-modulated, sympathetic nerve fibers to obtain direct, real-time measures of nerve activity during stimulation of the baroreflex, enabling continuous measurement of changes in sympathetic baroreflex sensitivity.
In conclusion, we report for the first time that catestatin, a peptide found throughout the nervous system, including efferent cardiovascular pathways, acts in the spinal cord as a potent negative modulator of the sympathoexcitatory effects of the neuropeptide PACAP-38.
The finding that PACAP-38 augments adaptive reflexes, and causes hypotension in the presence of catestatin, suggests that catestatin may interact with adenylate cyclase or phospholipase C; two intracellular mechanisms through which both peptides are thought to act. Furthermore, this suggests that catestatin may be a useful target for the future development of therapeutic agents.
Perspectives and Significance:
There is increasing evidence that elevated sympathetic tone contributes to the development of most forms of hypertension (8, 18, 33, 44) . This may be due to increased tonic RVLM activity (20-22, 37, 42) . Therefore, it is reasonable to propose that the increase in vasomotor tone seen in some hypertension (42) 
